Pregnant women who get prophylactic tocolytic therapy with 17-alpha-hydroxyprogesterone caproate because of a history of preterm delivery remain at high risk, researchers say. The study of 1,117 such women shows 44% developed preterm labor, with 23% going into labor at less than 34 weeks. Some 73% of women who developed preterm labor had recurrent episodes.

Related Summaries